FDA finalized guidance on software applications related to prescription drugs.

What it means

The FDA finalized a guidance document that clarifies when software applications used alongside prescription drugs—such as companion mobile apps, digital therapeutics, or connected device software—are considered part of a drug's official labeling or promotion. This settles a long-standing regulatory gray area by making drug sponsors formally responsible for the claims and content of these digital tools under existing drug labeling authorities.

Accuracy & sourcesGrounded

The claim is solid and well-sourced. It is directly based on the FDA's finalized guidance document 'Regulatory Considerations for Prescription Drug Use-Related Software,' published in the Federal Register on October 21, 2026. The reporting from STAT News and other reputable trade outlets (RAPS, Fierce Pharma) closely reflects the official text and its implications for drug sponsors.

How new